MACROGENICS INC (MGNX) Stock News
NASDAQ:MGNX - Nasdaq - US5560991094 - Common Stock - Currency: USD
MGNX Latest News, Press Relases and Analysis
MacroGenics to Participate in Upcoming Investor Conference
ROCKVILLE, MD, May 01, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on discovering, developing,...
MacroGenics to Participate in Upcoming Investor Conference
4 Medical Product Stocks to Buy From a Challenging Industry
The U.S. government's tariff imposition, especially on China, is likely to keep supply chains under pressure for the Zacks Medical Products industry. PODD, MGNX, CLRB and ALUR are likely to gain from the favorable factors.
Only 4% of finance leaders say firms are ‘maturing and scaling’ generative AI use
However, executives across business functions overwhelmingly characterized their companies as at least moving forward with generative AI initiatives.
Stock Market Whiplash: 5 Moves to Protect Your Portfolio Now
The S&P 500 (SNPINDEX: ^GSPC), the Dow Jones Industrial Average (DJINDICES: ^DJI), and the Nasdaq (NASDAQINDEX: ^IXIC) have been surprising investors daily with their movements, shifting rapidly according to news regarding President Donald Trump's tariff plans. The president earlier in the month announced a far-reaching set of tariffs on imports from countries worldwide, sending stocks tumbling as investors worried about the impact on U.S. corporate earnings and the economy. Since then, the U.S. paused the tariffs for 90 days to allow for negotiations, and he exempted electronics products from the duties -- at least temporarily.
Why AZEK Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
MacroGenics (MGNX) Q4 2024 Earnings Call Transcript
MGNX earnings call for the period ending December 31, 2024.
MacroGenics Provides Update on Corporate Progress and 2024 Financial Results
Fully enrolled LORIKEET, a randomized 150-patient Phase 2 study of lorigerlimab in combination with docetaxel in patients with mCRPCInitiating new LINNET...
MacroGenics Announces Date of Fourth Quarter and Full Year 2024 Financial Results Conference Call
ROCKVILLE, MD, March 06, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and...
MacroGenics Announces Date of Fourth Quarter and Full Year 2024 Financial Results Conference Call
MacroGenics to Participate in Upcoming Investor Conferences
ROCKVILLE, MD, Feb. 27, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conferences in March:
MacroGenics to Participate in Upcoming Investor Conferences
MacroGenics to Participate in Upcoming Investor Conference
ROCKVILLE, MD, Dec. 02, 2024 (GLOBE NEWSWIRE) -- -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on discovering, developing,...
MacroGenics to Participate in Upcoming Investor Conference
MacroGenics to Participate in Upcoming Investor Conferences
ROCKVILLE, MD, Nov. 06, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and...
MacroGenics to Participate in Upcoming Investor Conferences
MacroGenics (MGNX) Q3 2024 Earnings Call Transcript
MGNX earnings call for the period ending September 30, 2024.
MacroGenics Provides Update on Corporate Progress, Third Quarter 2024 Financial Results
Strengthened financial position resulting from recently announced MARGENZA® transaction and previously announced receipt of milestone payment from Incyte...
MacroGenics Announces Leadership Transition
Scott Koenig, M.D., Ph.D., to step down as President and CEOBoard to initiate search process to identify new CEO ROCKVILLE, MD, Oct. 30, 2024 (GLOBE...
MacroGenics Announces Leadership Transition
MacroGenics Announces Date of Third Quarter 2024 Financial Results Conference Call
ROCKVILLE, MD, Oct. 29, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and...
MacroGenics Announces Date of Third Quarter 2024 Financial Results Conference Call
MacroGenics Enters Into Agreement With TerSera Therapeutics for the Sale of MARGENZA®
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against MacroGenics, Inc. - MGNX
/PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against MacroGenics, Inc. ("MacroGenics" or the "Company") (NASDAQ: MGNX)....
MGNX Investors Have Opportunity to Join MacroGenics, Inc. Fraud Investigation with the Schall Law Firm
MacroGenics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - MGNX
/PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in MacroGenics, Inc. ("MacroGenics" or the "Company") (NASDAQ: MGNX) of a class action securities...
MGNX Investors Have Opportunity to Lead MacroGenics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MacroGenics
/PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against MacroGenics, Inc. ("MacroGenics" or the...
Shareholders that lost money on MacroGenics, Inc.(MGNX) Urged to Join Class Action - Contact The Gross Law Firm to Learn More
/PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of MacroGenics, Inc. (NASDAQ: MGNX). Shareholders who purchased shares of MGNX...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against MacroGenics and Vicor and Encourages Investors to Contact the Firm
Mentions: VICR
MGNX Deadline: MGNX Investors Have Opportunity to Lead MacroGenics, Inc. Securities Fraud Lawsuit
/PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock or sellers of puts of MacroGenics, Inc. (NASDAQ: MGNX)...
Contact Levi & Korsinsky by September 24, 2024 Deadline to Join Class Action Against MacroGenics, Inc.(MGNX)
/PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in MacroGenics, Inc. ("MacroGenics" or the "Company") (NASDAQ: MGNX) of a class action securities...
MGNX Deadline in 5 Days: Kessler Topaz Meltzer & Check, LLP Reminds MacroGenics, Inc. (MGNX) Investors of Filing Deadline in Class Action Lawsuit
/PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in...